MATA NATHAN L. 4

What Happened
Nathan L. Mata, Chief Scientific Officer of Belite Bio, sold a total of 666 American depositary shares (ADS) in four open‑market transactions on May 7, 2026, generating total proceeds of approximately $102,039. The individual trades reported were: 226 shares at $152.45 ($34,453); 428 shares at $153.56 ($65,725); 3 shares at $154.61 ($464); and 9 shares at $155.25 ($1,397). These were sales (routine disposition), not purchases.

Key Details

• Transaction date: May 7, 2026; Form 4 filed May 8, 2026 (timely).
• Total sold: 666 ADS for total proceeds ≈ $102,039.
• Reported prices: $152.35–$155.29 (individual trade prices listed above).
• Footnotes: Trades were executed under a Rule 10b5‑1 trading plan adopted 12/10/2025 (F2). Weighted‑average price ranges and willingness to provide per‑price breakdown are noted in footnotes F3–F5. F1 notes each ADS represents one ordinary share.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: S = Sale.

Context
Sales executed under a pre‑arranged 10b5‑1 plan are scheduled dispositions and are common for insiders managing personal tax or diversification needs; they do not, by themselves, indicate a change in insider sentiment. No other derivative exercises, gifts, or tax‑withholdings were reported in the provided transaction lines.